Cure8 research brief
This study suggests noninvasive vagus nerve stimulation (taVNS) can reduce colonic inflammation and change immune signals regionally in a mouse model of ulcerative colitis—supporting a possible neuroimmune approach worth further study for IBD.
Researchers in neuroimmune pathways and IBD, clinicians following experimental nonpharmacologic therapies, and developers of bioelectronic treatments.
This preclinical study tested transcutaneous auricular vagus nerve stimulation (taVNS) in a mouse model of ulcerative colitis (DSS-induced).
Daily 10-minute taVNS begun before colitis induction and continued through the experiment was associated with improved clinical and histologic scores and region-specific reductions in innate immune cells and proinflammatory cytokines in segments of the colon.
The reported effects were mainly local (cecum and colon regions) and involved decreases in granulocytes, macrophage numbers (mid-colon), and several cytokines (IL‑1β, TNF‑α, IL‑6, IFN‑γ, IL‑17A) with an increase in IL‑10 in the proximal colon; adaptive immune cell subsets were not changed.
The paper presents descriptive, region-specific immunologic measurements rather than randomized clinical outcomes in humans.
This is an animal (mouse) study reported as an abstract/full-text in Journal of Inflammation Research; it is preliminary preclinical research that helps understand mechanisms by which vagal stimulation might modulate colonic inflammation.
Preclinical (mouse) DSS-colitis model; findings are mechanistic and descriptive. Human relevance is uncertain until clinical trials are done.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study identifies a plant-derived polysaccharide (from the stem of Dendrobium huoshanense) that reduced inflammation and tissue injury in a mouse model of ulcerative colitis and points to GLP-1 signaling as a likely...
This preclinical study suggests an herbal capsule formulation reduced colitis severity and shifted markers of oxidative stress, inflammation, and ferroptosis in mice — signaling possible biological pathways for future...
The study identifies a plant extract that reduced colitis-like injury in mice and altered gut microbes and intestinal barrier markers, which could inform future preclinical work. For people with IBD, this is early-stage...
